Company Description
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.
It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
The company was founded in 2015 and is headquartered in Markham, Canada.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Pardeep Nijhawan |
Contact Details
Address: 100 Spy Court Markham, ON L3R 5H6 Canada | |
| Phone | 289 800 9600 |
| Website | edesabiotech.com |
Stock Details
| Ticker Symbol | EDSA |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001540159 |
| CUSIP Number | 27966L108 |
| ISIN Number | CA27966L3065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary and Director |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President |
| Peter John Weiler M.B.A, M.Sc. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |
| Jul 25, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 28, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 4, 2025 | ARS | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |